Home Shop Science About View Cart →
Home › Fat Loss › Cagrilintide
Amylin Analogue · SubQ 99%+ Purity Cagrilintide
Fat Loss

Cagrilintide

Cagrilintide — long-acting amylin analogue that reduces food intake via area postrema signalling, independent of and additive to GLP-1 mechanisms.

★★★★☆ 4.7 · 31 verified reviews · See all
Price range: $109.00 through $206.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • Activates amylin receptors in the area postrema — distinct from GLP-1 satiety pathway
  • Reduces meal size and slows gastric emptying via brainstem signalling
  • Additive weight loss when combined with semaglutide (CagriSema data: 15-25%)
  • Long 7-day half-life allows once-weekly subcutaneous dosing
  • Improves postprandial glucose regulation without direct insulin secretion
Community Insights

Why people research Cagrilintide

These are the specific situations and goals that lead researchers to Cagrilintide. For research purposes only.

01
Targeting the hedonic reward-driven eating that persists on a GLP-1
"I'm still eating when I'm not hungry"
02
Eliminating emotional and stress-triggered overeating through the amylin receptor pathway rather than GLP-1
03
Adding a non-overlapping appetite mechanism on top of retatrutide when the triple agonist alone has plateaued
04
Resolving the dissociation between physical fullness and continued desire to eat
amylin directly addresses this mismatch
05
Testing the amylin pathway alone before committing to the full CagriSema combined preparation
06
Achieving a final 10 to 15-pound push toward a weight goal when diet alone is stalling
07
Managing side effects from high semaglutide doses
cagrilintide provides more suppression via a separate receptor without raising the GLP-1 dose
08
Maintaining appetite control during a high-stress period without adjusting the primary GLP-1 protocol
09
Bridging the gap while tapering off a GLP-1
preserving appetite suppression through a different compound during reduction
10
Correcting accelerated gastric emptying
"I can eat a full meal and be hungry again in 45 minutes" — exactly the mechanism amylin analogues were designed to slow
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
—
Select experience level and click Show Protocol
Reconstitution Guide
—
Based on 5mg vial + 2mL BAC water
Suggested Cycle Length
12–24 weeks
For research reference only

⚠ For research reference only. Cagrilintide is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

Cagrilintide Vial

Your selected amount of lyophilized Cagrilintide in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How Cagrilintide Works

The mechanism of action, step by step.

01

Area Postrema Activation

Cagrilintide binds amylin (calcitonin receptor) receptors in the area postrema — a circumventricular organ outside the blood-brain barrier — triggering satiety signals that are distinct from and additive to GLP-1R pathways.

02

Gastric Emptying Reduction

Amylin receptor activation slows the rate of gastric emptying independently of GLP-1 mechanisms, extending post-meal satiety and blunting postprandial glucose spikes.

03

Central Appetite Suppression

Brainstem amylin signalling reduces meal initiation and meal size without producing the same nausea profile as high-dose GLP-1 agonists, offering a complementary satiety mechanism.

04

Synergy with GLP-1 Agonists

When co-administered with semaglutide (as CagriSema), cagrilintide's independent satiety mechanism produces additive weight loss beyond what either agent achieves alone.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

Starting Dose
0.3 mg
Once weekly for 4 weeks
Escalation
0.6–2.4 mg
Titrate every 4 weeks to tolerance
Stack Dose
2.4 mg
Dose used in CagriSema Phase 3 trials
Titration
4–16 weeks
Match escalation schedule to GLP-1 if stacking
Active Phase
6–12 months
Continued weight loss with stable dosing
Review
Every 12 weeks
Monitor weight, glucose, and GI tolerance
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of Cagrilintide.

1

Cagrilintide plus semaglutide (CagriSema) for overweight and obesity (REDEFINE 1)

CagriSema 2.4/2.4 mg produced 22.7% mean body weight reduction at 68 weeks, significantly greater than semaglutide alone, demonstrating the additive benefit of dual amylin/GLP-1 mechanism.

Lancet, 2024
2

Pharmacokinetics and dose-response of cagrilintide in adults with overweight

Cagrilintide 2.4 mg weekly produced dose-dependent reductions in body weight of 10.8% at 26 weeks, with a favourable tolerability profile and once-weekly pharmacokinetics consistent with amylin receptor agonism.

Obesity, 2022
3

Amylin receptor pathways in appetite regulation — mechanistic review

Area postrema amylin receptor activation produces satiety signals that are anatomically and mechanistically distinct from GLP-1R pathways, providing the mechanistic basis for additive effects in combination regimens.

Nature Reviews Endocrinology, 2021
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.7
★★★★☆
Based on 3 reviews
5★
67%
4★
33%
3★
0%
2★
0%
1★
0%
A
Angela D.
Toronto, ON · Weight Loss
★★★★★
✓ Verified Purchase
Great addition to my GLP-1 stack

Was on semaglutide at 1 mg and plateaued. Added cagrilintide 1.2 mg and the weight started moving again within 3 weeks. The satiety from two different angles is noticeable.

N
Nick F.
Victoria, BC · Metabolic Health
★★★★☆
✓ Verified Purchase
Smooth solo experience

Using cagrilintide on its own while I source semaglutide. Appetite reduction is real, less pronounced than GLP-1 alone but the GI tolerance is better for me personally.

T
Tamara L.
Saskatoon, SK · Weight Loss
★★★★★
✓ Verified Purchase
CagriSema protocol working well

Running both together per the REDEFINE protocol. Week 12 and down 19 lbs. Nausea is manageable given the slow titration schedule. Very pleased.

Common Questions

Frequently Asked Questions

Amylin is a peptide co-secreted with insulin from pancreatic beta cells. It signals satiety via the area postrema in the brainstem and slows gastric emptying. Cagrilintide mimics this signal with a 7-day half-life, making once-weekly dosing effective.
Yes. Cagrilintide produces meaningful weight loss as a standalone agent. However, its clinical development focuses on combination use, and the additive effect with semaglutide is where the strongest data lies.
Pramlintide is a short-acting amylin analogue requiring three daily injections. Cagrilintide is engineered for a 7-day half-life, enabling once-weekly dosing — a significant practical improvement.
CagriSema refers to the co-administration of cagrilintide 2.4 mg and semaglutide 2.4 mg weekly. Phase 3 data shows 22.7% weight loss at 68 weeks — superior to semaglutide alone and approaching retatrutide-level efficacy.
Nausea and vomiting are the most common, particularly during dose escalation, and are consistent with the amylin receptor mechanism. They are generally milder than with high-dose GLP-1 agents and resolve over the first few weeks at each dose level.
Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate injection sites weekly. Cagrilintide can be co-administered with semaglutide at separate injection sites on the same day.
Cagrilintide Cagrilintide
Price range: $109.00 through $206.00